Nephroblastoma: treatment during 1970-3 and the effect on survival of inclusion in the first MRC trial.
Nephroblastoma: treatment during 1970-3 and the effect on survival of inclusion in the first MRC trial.
复制标题
肾母细胞瘤：1970 年 3 月期间的治疗以及纳入第一次 MRC 试验对生存的影响。
作者：
E. Lennox;C. Stiller;P. H. Jones;L. Wilson
1970年，英国有3313名儿童被诊断为肾母细胞瘤。从1970年10月第一次医学研究理事会肾母细胞瘤研究开始到1973年底，98名儿童（占所有合格儿童的57%）被纳入试验。在313名儿童中，288名（92%）接受了肾切除术，248名（79%）接受了一个疗程的放疗，267名（85%）接受了至少4天的化疗。三年生存率为58%;试验中儿童的生存率（77%）明显优于符合试验条件但未入选的儿童（58%）。在专门的儿童医院和教学医院接受肾切除术的儿童比在其他地方接受治疗的儿童存活率更高。所有患有肾母细胞瘤的儿童都应根据明确的方案进行治疗，该方案考虑到儿童的年龄和肿瘤的阶段，并包括一个完整的维持化疗疗程。
In 1970-3 313 children were diagnosed as having nephroblastoma in Great Britain. From the start of the first Medical Research Council nephroblastoma study in October 1970 until the end of 1973, 98 children (57% of all eligible children) were included in the trial. Of the 313 children, 288 (92%) had a nephrectomy, 248 (79%) received a course of radiotherapy, and 267 (85%) were given at least four days' chemotherapy. The three-year survival rate was 58%; the rate among children in the trial (77%) was significantly better than that among children who were eligible for the trial but not included (58%). Children who had nephrectomies at specialised children's and teaching hospitals had a higher survival rate than those treated elsewhere. All children with nephroblastoma should be treated according to well-defined protocols which take into account the age of the child and the stage of the tumour and include a full course of maintenance chemotherapy.